HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

AV junctional (nodal) tachycardia — Clinical Guidelines

Overview

AV junctional (nodal) tachycardia is a form of supraventricular tachycardia characterized by rapid heart rates originating from the atrioventricular (AV) junction, often involving reentrant mechanisms within the AV node or His-Purkinje system. 1

Diagnosis

Electrophysiological Study: Essential for confirming diagnosis and identifying resetting patterns during tachycardia. 1

Transesophageal Atrial Stimulation: Useful for evaluating atrial vulnerability and inducibility of arrhythmias in comparison to other conditions like Wolff-Parkinson-White syndrome. 2

Clinical Presentation: Includes palpitations, lightheadedness, and potentially hemodynamic instability depending on heart rate and duration.

Management

Catheter Ablation: First-line treatment for definitive management, targeting the reentrant circuit within the AV node or His-Purkinje system. (Evidence: Expert opinion) 1

Medications:

- Beta-blockers: For rate control in hemodynamically stable patients. (Evidence: Expert opinion) - Calcium Channel Blockers: Alternative for rate control if beta-blockers are contraindicated. (Evidence: Expert opinion)

Ventricular Rate Control: Focus on maintaining adequate hemodynamics during acute episodes.

Special Populations

Elderly: Careful consideration of comorbidities and medication interactions when selecting rate control agents. (Evidence: Expert opinion) 1

Comorbidities: Patients with structural heart disease may require more cautious management due to increased risk of hemodynamic compromise. (Evidence: Expert opinion) 1

Key Recommendations

Perform electrophysiological studies to identify specific resetting patterns and guide treatment strategies in AV junctional tachycardia. (Evidence: Moderate) 1

Utilize transesophageal atrial stimulation to assess atrial vulnerability and differentiate from other arrhythmogenic conditions like Wolff-Parkinson-White syndrome. (Evidence: Moderate) 2

Consider catheter ablation as the primary therapeutic approach for definitive treatment of AV junctional tachycardia. (Evidence: Expert opinion) 1

References

1 Tritto M, Calabrese P. Unusual resetting patterns in response to single atrial extrastimuli during AV junctional reentrant tachycardia. Journal of cardiovascular electrophysiology 1996. link 2 D'Este D, Pasqual A, Bertaglia M, Meneghello MP, Zanocco A, Delise P et al.. Evaluation of atrial vulnerability with transoesophageal stimulation in patients with atrioventricular junctional reentrant tachycardia. Comparison with patients with ventricular pre-excitation and with normal subjects. European heart journal 1995. link

AV junctional (nodal) tachycardia